Literature DB >> 6790

Microsomal reductive glycosidase.

N R Bachur, M Gee.   

Abstract

Rat liver microsomes contain a phenobarbital inducible, NADPH dependent, reductive glycosidase capable of cleaving several anthracycline antibiotics, including adriamycin and daunorubicin, to deoxyaglycone products. The pH optimum for the reaction ranges from 7 to 7.4, and no metal requirements are noted. Molecular oxygen reversibly inhibits the microsomal enzyme greater than 95% at 20% oxygen partial pressure. Carbon monoxide, SKF 525A and sulfhydryl reagents are not inhibitory to the reaction, but the enzyme is sensitive to Cu++ and Zn++. Since the intact glycoside is necessary for conversion to the deoxyaglycone and a possible intermediate hydroxylated aglycone is not reduced to the deoxyaglycone, a concerted reaction mechanism is proposed. The reductive glycosidase activity is also present in rat brain, kidney and other tissues. Sensitivity of this enzyme to molecular oxygen suggests a possible regulatory role for the enzyme in vivo.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 6790

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  10 in total

1.  Capillary electrophoresis monitors enhancement in subcellular reactive oxygen species production upon treatment with doxorubicin.

Authors:  Angela R Eder; Edgar A Arriaga
Journal:  Chem Res Toxicol       Date:  2006-09       Impact factor: 3.739

2.  7-Deoxy-13-dihydrodaunomycinone in cultures of Streptomyces coeruleorubidus.

Authors:  J Matĕjů; J Vokoun; M Blumauerová; Z Vanĕk
Journal:  Folia Microbiol (Praha)       Date:  1978       Impact factor: 2.099

3.  Adriamycin uptake and metabolism in organotypic culture of A549 human adenocarcinoma cells according to the exposure time.

Authors:  S Chevillard; P Vielh; G Bastian; J Coppey
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

4.  Metabolism of daunorubicin in sensitive and resistant Ehrlich ascites tumor cells. Determination by high pressure liquid chromatography.

Authors:  D Londos-Gagliardi; R Baurain; J Robert; G Aubel-Sadron
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

5.  Biotransformations of anthracyclinones in Streptomyces coeruleorubidus and Streptomyces galilaeus.

Authors:  M Blumauerová; E Královcová; J Matĕjů; J Jizba; Z Vanĕk
Journal:  Folia Microbiol (Praha)       Date:  1979       Impact factor: 2.099

6.  Disposition of 14C-labelled 4'-epidoxorubicin and doxorubicin in the rat. A comparative study.

Authors:  F Arcamone; M Lazzati; G P Vicario; G Zini
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

7.  Effect of phenytoin on the pharmacokinetics of doxorubicin and doxorubicinol in the rabbit.

Authors:  B J Cusack; D A Tesnohlidek; V L Loseke; R E Vestal; D E Brenner; R D Olson
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

8.  Influence of the cardioprotective agent dexrazoxane on doxorubicin pharmacokinetics in the dog.

Authors:  J R Baldwin; B A Phillips; S K Overmyer; N Z Hatfield; P K Narang
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

9.  Hepatic metabolism of doxorubicin in mice and rats.

Authors:  P Vrignaud; D Londos-Gagliardi; J Robert
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1986 Apr-Jun       Impact factor: 2.441

10.  Mathematical model for adriamycin (doxorubicin) pharmacokinetics.

Authors:  S D Reich; F Steinberg; N R Bachur; C E Riggs; R Goebel; M Berman
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.